Inception Sciences is a pioneering brand in the field of biotechnology, founded in 2011 through a collaboration with Versant Ventures. They have established themselves as a leader in creating and launching transformative new biotechnology companies. With their integrated expertise in chemistry, biology, and DMPK (drug metabolism and pharmacokinetics), Inception Therapeutics has successfully raised over $200 million in funding from pharmaceutical partners and investors.

Led by a team of accomplished professionals, Inception Sciences is driven by their mission to advance drug discovery and develop novel therapeutics. Their executive leadership includes Jeremy Caldwell as President and CEO, Richard Glynne as Chief Scientific Officer, Don Hertzog as Head of Chemistry, and Dallas Jones as Executive Director and Head of Biology. Inception Sciences supports the incubation of several new companies, providing essential resources and expertise to advance their biology and drug discovery efforts.

Their board of directors, including individuals like Tom Woiwode, Benjamin F. Cravatt, and Tom Daniel, bring extensive experience and knowledge to drive the success of these ventures. Through their innovative approaches and commitment to excellence, Inception Sciences continues to shape the future of biotechnology and contribute to significant advancements in drug discovery and development